Kangbridge Capital leads over 1 billion yuan Series A funding for Everbridge Group, strengthening its leading position in innovative medical devices for high-prevalence chronic diseases.

EverBridge Group is a leading Asian medical technology group that upholds the core philosophy of “rapid yet high-quality scaling.” Leveraging its platform-based advantages, the company accurately identifies global industry trends and market demands.With the scientific research capabilities of its Advanced Medical Technology Institute and the technological support of its Six Shared Core Technology Centers,EverBridge Group has achieved “from 0 to 1” breakthroughs in R&D value creation across peripheral vascular interventions, neuroscience, and integrated cancer diagnostics & therapeutics. Furthermore, driven by its EBS™ Excellence System—a lean value management framework—the group has realized “from 1 to N” commercial value multiplication.Renowned for its exceptional product quality, comprehensive portfolio, efficient manufacturing capabilities, and robust sales network,EverBridge Group has earned widespread recognition in the industry.